Results from VENTURE Phase 2 Study of Subcutaneous VK2735 in Obese Patients and Phase 1 Trial of Oral VK2735 in Healthy Subjects to be Presented SAN DIEGO, Oct. 28, 2024 /PRNewswire/ -- Viking ...

Notes: 1) Observed values, no imputation for missing data. 2) Includes all participants who met the criteria for MetS at baseline and enough MetS component Week 13 data collected to determine MetS ...

SAN DIEGO, June 25, 2025 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and ...

Results from VENTURE Phase 2 Study of Subcutaneous VK2735 in Obese Patients and Phase 1 Trial of Oral VK2735 in Healthy Subjects to be Presented One presentation will summarize results from the ...

Brian Lian, President and CEO, reported that "the Viking team continued to focus on execution of our core clinical strategy," emphasizing advancement of both oral and subcutaneous VK2735 programs. "We ...